Thomas Cavanaugh
CIK: 0002151011
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
JNJ
JOHNSON & JOHNSON
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Cavanaugh Thomas
Cavanaugh Thomas (SEC CIK 0002151011) files insider reports with the SEC as EVP WW Chair, Innovative Med. of JOHNSON & JOHNSON (JNJ).
Signal8 holds 1 ownership filing by Cavanaugh Thomas, a Form 3, filed on Sep 1, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Cavanaugh Thomas's filings is in NEW BRUNSWICK, NJ.
Other insiders filing for JOHNSON & JOHNSON (JNJ)
- Pinto Daniel E, Director
- Woods Eugene A., Director
- HEWSON MARILLYN A, Director
- Schmid Timothy, EVP, WW Chair, MedTech
- Taubert Jennifer L, EVP, WWC. Innovative Medicine
- Duato Joaquin, CEO and Chairman of the Board